Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,076 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK. Han SW, et al. Among authors: kim dw, kim ty, kim j, kim yt, kim nk, kim jh. J Clin Oncol. 2005 Apr 10;23(11):2493-501. doi: 10.1200/JCO.2005.01.388. Epub 2005 Feb 14. J Clin Oncol. 2005. PMID: 15710947 Clinical Trial.
The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, Jheon S, Sung SW, Kim JH. Kang CH, et al. Among authors: kim dw, kim yt, kim jh. Lung Cancer. 2010 Jun;68(3):478-83. doi: 10.1016/j.lungcan.2009.07.004. Epub 2009 Aug 15. Lung Cancer. 2010. PMID: 19683826
Differences in the expression profiles of excision repair crosscomplementation group 1, x-ray repair crosscomplementation group 1, and betaIII-tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival.
Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, Jheon S, Sung SW, Kim JH. Kang CH, et al. Among authors: kim dw, kim yt, kim jh. J Thorac Oncol. 2009 Nov;4(11):1307-12. doi: 10.1097/JTO.0b013e3181b9f236. J Thorac Oncol. 2009. PMID: 19745766 Free article.
Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
Koh Y, Jang B, Han SW, Kim TM, Oh DY, Lee SH, Kang CH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Kim YW, Kim JH, Heo DS, Bang YJ. Koh Y, et al. Among authors: kim dw, kim ty, kim tm, kim yt, kim yw, kim jh. J Thorac Oncol. 2010 Mar;5(3):320-5. doi: 10.1097/JTO.0b013e3181ce684f. J Thorac Oncol. 2010. PMID: 20087230 Free article.
2,076 results